Vision
To advance the development and utilization of safe and efficacious medicines through the application of Quantitative Systems Pharmacology (QSP)
- Advance the science of QSP by fostering a community for the exchange of ideas and knowledge
- Promote the application of QSP in drug development and regulatory decision-making
- Develop and maintain information resources for its members, including establishment of “best practices” for QSP approaches
- Facilitate communication and advance knowledge through sponsored sessions at professional meetings, white papers, discussion groups, and publications
QSP SIG Leadership Team
|
Dr. Benjamin Ribba holds a Master degree and PhD in applied mathematics. He started his career in 2001 as a fellow of a European Research Grant dedicated to application of mathematics to biology and medicine. He was successively researcher in computer science at Inria from 2008 to 2015 in France where he focused his research on the development and application of mathematical models to address questions around optimization of the efficacy and delivery of anti-cancer drugs in patients. In 2015, he joined Roche Pharma Research and Early Development. He is the author of ca. 50 publications in peer-reviewed scientific journals. |
|
Dr.Ioannis (Yannis) P. Androulakis is a Professor in the Department of Biomedical Engineering, the Department of Chemical & Biochemical Engineering, and holds an Adjunct faculty position in the Department of Surgery at the Rutgers – Robert Wood Johnson Medical School. He has a BS degree from NTUA, Athens, Greece; MS/Ph.D. from Purdue University, all in Chemical Engineering followed by postdoctoral training at Princeton University. Before joining Rutgers, he was with ExxonMobil’s Corporate Strategic Research Laboratories in NJ for several years, where he eventually became a technical program leader. His research focuses on quantitative systems biology and pharmacology of inflammation, emphasizing the interactions between the circadian, endocrine, and immune systems. He is a Fellow of the American Institute for Medical and Biological Engineering and a Fellow of the American Institute of Chemical Engineers. |
|
Dr Lourdes Cucurull-Sanchez has 18 years of experience in the Pharma industry. As part of the model-informed drug discovery and development (MID3) paradigm, she currently drives the implementation of QSP modelling strategies at GSK, with focus on the Oncology Development portfolio at GSK. She has a passion for embedding innovative modelling methods into decision-making in order to reduce drug attrition. She is a founder and active board member of the UK QSP Network, where she led the publication of a set of recommendations on best practices to maximize QSP model impact and repurposing. She is also a GSK Fellow and a member of the IQ Consortium QSP WG2, ASCPT and ISoP. Lourdes joined GSK in 2012, initially as a QSP modelling manager in the Computational Biology group, and currently as a director in the Clinical Pharmacology Modelling and Simulation department. Prior to GSK, she spent 8 years modelling at Pfizer, firstly as a as a machine learning (ML) computational chemist and later on as a QSP modeler under the management of Piet van der Graaf. She was awarded a W.E. Upjohn Award (2007) in the area of Innovation, Postdoctoral Research Associate at the University of Cambridge (QSAR and Machine Learning, 2004), PhD in Chemistry (Quantum Chemistry, 2000) at the Universitat Autonoma de Barcelona, and MPhil in Chemistry (X-ray Crystallography, 1995) at The University of Newcastle upon Tyne. |
|
Dr. Neha Murad is an Applied Mathematician with a PhD in Biomathematics and minor in Statistics from North Carolina State University. She is a senior data scientist in the Translational Computing team at Calico Life Sciences, where she uses a combination of epidemiological, bioinformatics and QSP models and tools to understand the biology that controls aging and lifespan. Prior to Calico, Neha was a postdoc at GSK where she was part of the Pharmacokinetics (PK) team and used systems models in combination with machine learning approaches to build Physiologically Based Pharmacokinetic (PBPK) Models. When not building math models, Neha loves to volunteer for events promoting mathematics in women and minorities. She is a AAAS IF/THEN Ambassador and is deeply involved in STEM outreach for middle and high school girls. |
|
Dr. Friedrich is the Chief Engineer at Rosa & Co, a drug development advisory firm that specializes in mechanistic QSP modeling. She holds BS degrees in Mathematics and Engineering Systems and Computation from MIT and a PhD in Management Science and Engineering from Stanford University. Dr. Friedrich has over 18 years of experience in developing and applying mathematical models of biological systems to support development of pharmaceuticals and consumer products. Her therapeutic area experience includes diabetes, blood disorders, CNS disorders, oncology/immuno-oncology, respiratory diseases, skin diseases, auto-immune diseases, and other immune system dysfunctions and inflammatory processes. Dr. Friedrich has a long-standing interest in advancing methodologies and applications for the effective use of mechanistic QSP models. While at Rosa, Dr. Friedrich developed and published the Model Qualification Method, a systematic qualification framework for mechanistic mathematical QSP models. In her previous role at Entelos, Dr. Friedrich spearheaded development of modeling methodologies and contributed to foundational mechanistic modeling patents, including on the use of virtual patients and virtual populations to explore biological variability and uncertainty, and on the use of mechanistic models in the identification of biomarkers. |
|
Dr. Jingqi Gong is a senior quantitative systems pharmacologist at AbbVie in the department of Clinical Pharmacology and Pharmcometrics, where she leads the effort of QSP modeling primarily supporting early oncology development. Jingqi received Ph.D. in Biomedical Sciences from Icahn School of Medicine at Mount Sinai in New York City, her Ph.D. research focused on systems pharmacology and mathematical models of cardiac electrophysiology. Jingqi has been engaging with ISoP and QSP SIG prior to her industry career, she received the Quality Trainee Awards at the American Conference of Pharmacometrics (ACoP9). |
Lourdes Cucurull-Sanchez (Vice-Chair)
Neha Murad (Communications Director)
Jingqi Gong (Secretary)2021 Steering Committee Members
- Jane Bai, PhD, Office of Clinical Pharmacology, Division of Applied Regulatory Science, United States Food and Drug Administration
- John Burke, PhD, President, CEO, and Co-founder at Applied BioMath, Adjunct Faculty, Harvard Medical School
- James Gallo, PharmD, PhD, Empire State Innovation Professor, SUNY Buffalo Department of Pharmaceutical Sciences
- Rukmini Kumar, PhD, Chief Scientist and Co-founder, Vantage Research
- Tarek Leil, PhD, Group Director, Quantitative Clinical Pharmacology, BMS, Adjunct Faculty, University of Pittsburgh School of Pharmacy
- CJ Musante, PhD, Senior Scientific Director, Head of Quantitative Systems Pharmacology, Pfizer
- Mark Peterson, PhD, Senior Director, Modeling & Simulation, Vertex
- Aleksander S. Popel, Professor, Department of Biomedical Engineering, School of Medicine, Johns Hopkins University
- Saroja Ramanujan, PhD, Principal Scientist & Associate Director, Translational & Systems Pharmacology, Head of QSP, Genentech Inc.
- Matthew Riggs, PhD, Chief Science Officer, Metrum Research Group
- Julio Saez-Rodriguez, PhD, Professor of Medical Bioinformatics and Data Analysis, Heidelberg University Hospital, Group Leader, EMBL
- Stephan Schmidt, PhD, FCP, Endowed Certara Professor, University of Florida College of Pharmacy
- Birgit Schoeberl, PhD, Global Head Modeling and Simulation, PK Sciences at Novartis Institutes for BioMedical Research
- Iñaki F. Trocóniz, PhD, Professor, Universidad de Navarra, Pharmacometrics & Systems Pharmacology
- Paolo Vicini, PhD, Vice President, Development Sciences, Kymab Ltd
- Yuching Yang, PhD, Office of Clinical Pharmacology, Division of Pharmacometrics, United States Food and Drug Administration
What is Quantitative Systems Pharmacology?
The white paper below represents the NIH’s attempt to define the
opportunities and challenges facing the field of quantitative systems
pharmacology (QSP). The paper recommends the adoption of a holistic
approach to understanding the interaction of drugs with human biology.
The paper further notes that this will require the collaboration and
training of scientists from multiple disciplines, from pharmacology to
chemistry to computer science. We look forward to hearing from ideas
from our SIG members about how these disciplines can be effectively
synthesized so that QSP can continue to grow as a field.
www.nigms.nih.gov/News/reports/Documents/SystemsPharmaWPSorger2011.pdf
Are you interested in receiving updates and participating in SIG discussions? Join the ISoP QSP SIG today, click here. You can also participate in the QSP discussion forum at https://discuss.go-isop.org/c/systems-pharmacology
For additional information regarding the QSP SIG, please visit our google site: https://sites.google.com/view/isopqspsig/home